Biodistribution Studies Demystified: Informing The Efficacy Of Cutting Edge Therapeutics

For viral vectors, the rapid expansion of clinical pipelines and the number of potential candidates moving toward commercial approval have skyrocketed since the milestone approval of Glybera, a recombinant AAV therapy for hereditary lipoprotein lipase deficiency, by the U.S. FDA in 2012.

The inherent benefits of ddPCR technology are gaining traction in biodistribution studies. Determination of biodistribution in both the preclinical and early clinical phases is an essential aspect of developing these novel therapies. Learn more about the methods utilized in biodistribution and why it is a critical tool in cell and gene-based therapeutics.